TSS
CBIO

Two Sigma Securities’s Crescent Biopharma CBIO Stock Holding History

Two Sigma Securities’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-157
Closed -$3.31K – 1722
2025
Q1 		$3.31K Buy
+157
New +$4.2K ﹤0.01% 1328
2024
Q4 		– Sell
-222
Closed -$3.75K – 2268
2024
Q3 		$3.75K Buy
+222
New +$4.66K ﹤0.01% 2685
2023
Q3 		– Sell
-110
Closed -$19.1K – 3132
2023
Q2 		$19.1K Buy
+110
New +$18.4K ﹤0.01% 2515

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Two Sigma Securities's CBIO Position: Q2 2025 in Review

Two Sigma Securities sold out of Crescent Biopharma (CBIO) in Q2 2025, closing a stake of 157 shares — an estimated $3.31K sold.

Two Sigma Securities first reported a position in CBIO in Q2 2023 and held it in 3 quarters. The position peaked at $19.1K in Q2 2023. 30 funds tracked by Wall St. Rank hold CBIO as of Q2 2025.

  • Two Sigma Securities reported no remaining Crescent Biopharma position as of Q2 2025 after selling out during the quarter.
  • Two Sigma Securities sold 157 Crescent Biopharma shares in Q2 2025, an estimated $3.31K.
  • Two Sigma Securities first reported a position in Crescent Biopharma in Q2 2023 and held it in 3 quarters.
  • Two Sigma Securities's Crescent Biopharma position peaked at $19.1K in Q2 2023.
  • 30 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2025.

Based on Two Sigma Securities's 13F filing for Q2 2025, filed 14 Aug 2025.